CluePoints, a leading provider of Centralised Statistical Monitoring (CSM) solutions for clinical trials, was honoured with the award for the 'Best Technological Development in Clinical Trials' at the 2014 Scrip Awards held at The Lancaster Hotel, London on 3 December. The award, sponsored by the MCT Congress, recognises 'CluePoints in the Cloud' as the ultimate quality oversight and risk-based monitoring (RBM) application developed to determine the quality and integrity of clinical trials data.

With customers already able to utilise CluePoints' CSM solution as a service, the company has been continually working to enhance the usability of its platform to meet the industry’s current needs and taking into consideration the feedback from its clients. In particular the need for a solution that enables companies to take full control of their own RBM activities using all the data within their clinical databases. In response, CluePoints launched a solution to enable customers to drive their own analyses through a new web platform. Taking away the need for processes to be solely overseen by a separate organisation, the solution puts the management of RBM processes firmly in the hands of sponsors and CROs.

"It is an honour to receive an award that recognises the value of our CSM solution developed to empower sponsors and CROs to objectively and independently determine both the quality and integrity of their trial data", says Fran?ois Torche, cief executive office, of CluePoints. "I would like to extend continual thanks to all our customers and of course the CluePoints' team who developed this award-winning first-of-its-kind cloud-based platform."

CluePoints is a Central Statistical Monitoring solution that has been designed and perfected over the last 10 years. It employs unique statistical algorithms to determine the quality, accuracy and integrity of clinical trial data both during and after study conduct. Aligned with guidance from the FDA and EMA, CluePoints is deployed to support traditional on-site monitoring and to drive a risk-based monitoring strategy. The value of using CluePoints lies in its powerful and timely ability to identify anomalous data and site errors allowing improvement in clinical data quality, optimisation of on-site monitoring and a significant reduction in overall regulatory submission risk.